A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker

Abstract

The combination of docetaxel, cisplatin, and S-1 (DCS) chemotherapy is expected to be a promising regimen for advanced gastric cancer. This study was performed to evaluate the efficacy and safety of neoadjuvant DCS chemotherapy for locally advanced resectable gastric cancer. Patients with locally advanced gastric cancer received 2 courses of preoperative chemotherapy with S-1 (40 mg/m2 b.i.d.) on days 1–14 and docetaxel (60 mg/m2) plus cisplatin (60 mg/m2) on day 8 every 3 weeks, followed by standard curative surgery within 4–8 weeks. The primary endpoint was R0 resectability. Expression of damage DNA binding protein complex subunit 2 (DDB2)/excision repair cross-complementing 1 (ERCC1) in the pretreated tumor tissues was examined by immunohistochemistry. A total of 43 patients received neoadjuvant chemotherapy. The response rate was 74.4 %, and disease control ratio was 100 %. Grade 4 neutropenia developed in 53.5 % of patients and febrile neutropenia in 16.3 %. Non-hematological grade 3/4 adverse events were anorexia (23.3 %), nausea (14.0 %), and diarrhea (23.3 %), but these were generally transient and manageable. The proportion of R0 resections in the 43 eligible patients was 90.7 %, and a pathological response was found in 65.9 % of patients. There were no treatment-related deaths and no major surgical complications. The accuracy of the combination of DDB2 and ERCC1 expression for predicting chemoresistance was 82.5 %. Preoperative treatment with DCS combination for locally advanced gastric cancer demonstrated a sufficient R0 resection rate and a good pathological response with manageable toxicities. The DDB2/ERCC1-high phenotype, as determined by immunohistochemistry, may be useful predictor of resistance to DCS chemotherapy.

DOI: 10.1007/s00280-013-2073-5

5 Figures and Tables

020040020132014201520162017
Citations per Year

557 Citations

Semantic Scholar estimates that this publication has 557 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Hirakawa2013API, title={A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker}, author={Masahiro Hirakawa and Yasushi Sato and Hiroyuki Ohnuma and Tetsuji Takayama and Tamotsu Sagawa and Takayuki Nobuoka and Keisuke Harada and Hiroshi Miyamoto and Yasuhiro Sato and Yasuo Takahashi and Shinich Katsuki and Michiaki Hirayama and Minoru Takahashi and Michihiro Ono and Masahiro Maeda and Kohichi Takada and Tsuyoshi Hayashi and Tsutomu Sato and Koji Miyanishi and Rishu Takimoto and Masayoshi Kobune and Koichi Hirata and Junji Kato}, journal={Cancer Chemotherapy and Pharmacology}, year={2013}, volume={71}, pages={789-797} }